Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Recruiting now

Conditions studied: Non-small Cell Lung Cancer (NSCLC)

In brief

This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.

Key facts

Study ID
NCT05100069
Run by
Takeda
People needed
500
Starts
2021-11-01
Expected to finish
2030-09-30
Last updated by the study team
2026-03-17

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.